<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03348098</url>
  </required_header>
  <id_info>
    <org_study_id>AHEAD TB001</org_study_id>
    <nct_id>NCT03348098</nct_id>
  </id_info>
  <brief_title>Clinical Study of Neoadjuvant Therapy With Apatinib and Paclitaxel in Local Advanced Triple-negative Breast Cancer</brief_title>
  <official_title>Tianjin Medical University Cancer Institute and Hospital</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tianjin Medical University Cancer Institute and Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tianjin Medical University Cancer Institute and Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy and safety of apatinib in patient with&#xD;
      TNBC&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      NACT (Neoadjuvant chemotherapy) Increasingly widespread in clinical practice, there is still&#xD;
      a substantial proportion of the patients NACT After failing to obtain ORR DCR , NACT Did not&#xD;
      receive ORR DCR Patient access ORR DCR Patients have a higher risk of recurrence, and&#xD;
      complete NACT The patient, the current standard therapy in the secondary stage of&#xD;
      chemotherapy is no longer used, but non-ORR non-DCR After neo-adjuvant chemotherapy in&#xD;
      patients with postoperative chemotherapy is worth exploring. Targeted drugs refer to&#xD;
      interfere with tumor specific molecular processes and achieve inhibit or block the&#xD;
      progression of drugs, its functioning is based on normal cells and tumor cells, differences,&#xD;
      which makes the target specificity and side effects of the drug. Target drug is a pioneer in&#xD;
      precision treatment of its interpretation of the individualized treatment based on the&#xD;
      standard treatment. NCCN guidelines recommend paclitaxel in neoadjuvant chemotherapy is NACT&#xD;
      first-line choice. At the Apatinib for dasatinib therapy in previous studies of breast cancer&#xD;
      has a high level of performance, the Apatinib for dasatinib combined with paclitaxel in&#xD;
      neoadjuvant therapy for breast cancer efficacy and safety is better than traditional&#xD;
      treatments, is worthy of question.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">September 6, 2017</start_date>
  <completion_date type="Anticipated">December 6, 2018</completion_date>
  <primary_completion_date type="Anticipated">July 6, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>ORR</measure>
    <time_frame>ten months</time_frame>
    <description>objective response rate</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>DCR</measure>
    <time_frame>ten months</time_frame>
    <description>disease control rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>pCR</measure>
    <time_frame>ten months</time_frame>
    <description>pathologic complete response</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DFS</measure>
    <time_frame>ten months</time_frame>
    <description>disease free survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events [Safety]</measure>
    <time_frame>ten months</time_frame>
    <description>incidence of participants with treatment-related adverse events as assessed by NCI CTCAE v4.03</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Triple Negative Breast Cancer</condition>
  <arm_group>
    <arm_group_label>single arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Apatinib Combined With Paclitaxel in Neoadjuvant Therapy of Locally Advanced Exploratory Research on Single-arm of TNBC</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Apatinib</intervention_name>
    <description>500 mg, po, qd. 12weeks</description>
    <arm_group_label>single arm</arm_group_label>
    <other_name>YN968D1</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <description>drug: Paclitaxel ,80mg/m2, d1, Once a week , A total of 12 weeks; 3 weeks as a cycle</description>
    <arm_group_label>single arm</arm_group_label>
    <other_name>Taxol</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. patients between18 and 75 Years old;&#xD;
&#xD;
          2. patients with locally advanced breast cancer (TNM periodization:T is equal to or&#xD;
             greater than 2,N is equal to 1,M is equal to 0)&#xD;
&#xD;
          3. clear for immunohistochemical is that: estrogen receptor-negative (ER-), progesterone&#xD;
             receptor-negative (PR-), the human epidermal growth factor receptor 2 is Negative (&#xD;
             IHC Her-2 0/+ , If ER- 、 PR- But Her-2 ++ , You need to do FISH/CISH Testing confirmed&#xD;
             that Her-2 Amplification is negative);&#xD;
&#xD;
          4. The ECOG score is between 0 to 2 points;&#xD;
&#xD;
          5. The expected lifetime is ≥3 months;&#xD;
&#xD;
          6. Major organ function is normal, that meet the following criteria:&#xD;
&#xD;
               1. Blood test standards subject to:&#xD;
&#xD;
                  HB≥90 g/L ;&#xD;
&#xD;
                  ANC≥1.5×109 /L ;&#xD;
&#xD;
                  PLT≥100×109 /L ;&#xD;
&#xD;
               2. Biochemical examination must meet the following criteria:&#xD;
&#xD;
             TBIL≤1.5xULN ( upper limit of normal value ) ;&#xD;
&#xD;
             ALT AST≤2.5×ULN ;&#xD;
&#xD;
             Serum Cr≤1.5×ULN And endogenous creatinine clearance rate ≥50 mL/min (Cockcroft-Gault&#xD;
             formula ) ;&#xD;
&#xD;
          7. the women of childbearing age must do the pregnancy test ( serum or urine ) within 7&#xD;
             days when they are included in the trial, And the result was negative, and during the&#xD;
             trial and at the time of giving experimental drugs after 8 weeks using the appropriate&#xD;
             methods of contraception;&#xD;
&#xD;
          8. no difficulty in swallowing, swallowing oral medications;&#xD;
&#xD;
          9. the participants volunteered to join this study should sign the informed consent&#xD;
             forms, have better compliance, work in with the follow-up&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. patients with pregnancy or lactation;&#xD;
&#xD;
          2. inflammatory breast cancer patients;&#xD;
&#xD;
          3. patients with several factors affecting medication (for example, inability to swallow,&#xD;
             such as nausea, vomiting, chronic diarrhea, and bowel obstruction);&#xD;
&#xD;
          4. injury or pathologic fracture;&#xD;
&#xD;
          5. people with high blood pressure and antihypertensive drug treatment could not be&#xD;
             reduced to within the normal range (systolic &gt;140 mmHg, diastolic pressure &gt;90 mmHg) ;&#xD;
&#xD;
          6. with ⅱ grade myocardial ischemia, poor control of arrhythmias or myocardial infarction&#xD;
             (including QTc interval men ≥450 Ms, female ≥470 Ms);&#xD;
&#xD;
          7. according to NYHA standard ⅲ~ⅳ -class heart insufficiency or heart ultrasound:&#xD;
             LVEF(left ventricular ejection fraction) &lt;50%;&#xD;
&#xD;
          8. the past 6 months have gastrointestinal bleeding within history or definite&#xD;
             gastrointestinal bleeding, such as: risk of bleeding oesophageal varicose ulcer&#xD;
             lesions, fecal occult blood, local activities ≥ (++) Into groups; such as the fecal&#xD;
             occult blood (+), requires endoscopy;&#xD;
&#xD;
          9. prior to participating in the study of 28 days abdominal fistula, perforation of the&#xD;
             gastrointestinal tract and abdominal abscesses;&#xD;
&#xD;
         10. positive patients of urinary protein (urine protein 2+ or above, or 24 -hour urine&#xD;
             protein &gt; 1.0g);&#xD;
&#xD;
         11. distant metastasis of patients with symptoms or are not controlled;&#xD;
&#xD;
         12. expected lifetime &lt; 3 months;&#xD;
&#xD;
         13. into the group before 28 days to accept other anticancer treatment;&#xD;
&#xD;
         14. other information: dysfunction of blood coagulation (INR&gt;1.5 or prothrombin time ( PT&#xD;
             )&gt; ULN+4 Seconds); Anticoagulant therapy are receiving antithrombotic or infection who&#xD;
             needed intravenous antibiotics; previously receiving bevacizumab treatment or other&#xD;
             anti- VEGF TKI Drug treatment, with a second tumor (except basal cell carcinoma and&#xD;
             cervical carcinoma in situ);&#xD;
&#xD;
         15. a history of immunodeficiency, including HIV testing positive, or suffer from other&#xD;
             acquired, congenital immune deficiency disease or have a history of organ&#xD;
             transplantation;&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hong MD Liu</last_name>
    <role>Study Chair</role>
    <affiliation>study principal investigator</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hong MD Liu, professor</last_name>
    <phone>18622221169</phone>
    <email>lh713@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>TianJin Medical University Cancer Institute and Hospital</name>
      <address>
        <city>Tianjin</city>
        <zip>300060</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hong MD Liu, professor</last_name>
      <phone>18622221169</phone>
      <email>lh713@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2017</verification_date>
  <study_first_submitted>November 9, 2017</study_first_submitted>
  <study_first_submitted_qc>November 15, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 20, 2017</study_first_posted>
  <last_update_submitted>November 27, 2017</last_update_submitted>
  <last_update_submitted_qc>November 27, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 28, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Triple negative breast cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Triple Negative Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Apatinib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>the plan to share IPD is under consideration</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

